No Data
Beijing Konruns Pharmaceutical (603590.SH): The "Construction project for a production base of 500 kg of Anti-tumor Active Pharmaceutical Ingredient" is proposed to be postponed to December 2026.
On December 16, Gelonghui reported that Beijing Konruns Pharmaceutical (603590.SH) announced that, based on the current progress of the "annual production of 500 kg Active Pharmaceutical Ingredient production base construction project," the company plans to extend the expected time for the project to become operational to December 2026, provided that there are no changes in the use of raised funds and investment scale.
Kangchen Pharmaceutical\'s 2024 Third Quarter Report
Beijing Konruns Pharmaceutical (603590.SH): The net income in the first three quarters is approximately 0.113 billion yuan, a decrease of 23.99% year-on-year.
Kang Chen Pharmaceuticals (603590.SH) announced on October 29th that its revenue for the first three quarters of 2024 was approximately 0.646 billion yuan, a decrease of 10.24% year-on-year; net income attributable to shareholders of the listed company was approximately 0.113 billion yuan, a decrease of 23.99% year-on-year; and the basic earnings per share was 0.7189 yuan.
Beijing Konruns Pharmaceutical (603590.SH): The late-stage esophageal squamous cell carcinoma stage III clinical study KC1036 is being conducted in an orderly manner according to plan.
Oct. 8th, Kangchen Pharmaceutical (603590.SH) stated during a specific research interview that KC1036 has made breakthroughs in clinical diversification, entering late-stage clinical research for stage Ⅲ esophageal squamous cell carcinoma. KC1036 is a multi-target receptor tyrosine kinase inhibitor independently developed by the company, and is systematically conducting multiple clinical trials as planned, with a focus on treating late-stage esophageal squamous cell carcinoma in clinical research for stage Ⅲ, maintaining local late-stage or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with PD-1 antibodies, and treating late-stage EWING sarcoma in adolescents aged 12 and above.
Kangchen Pharmaceutical 2024 Semi-Annual Report
Summary of Kangchen Pharmaceutical\'s 2024 Semi-Annual Report
